General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 2K7 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects human HLA-A. It targets an epitope within 23 amino acids from the extracellular domain.
Immunogen
KLH-conjugated linear peptide corresponding to 23 amino acids from the extracellular domain of human HLA-A.
Application
Quality Control Testing
Evaluated by Western Blotting in Raji cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected HLA-A in Raji cell lysate.
Tested Applications
Affinity Binding Assay: A representative lot of this antibody bound HLA-A peptide with a KD of 7.6 x 10-8 in an affinity binding assay.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected HLA-A in Raji cells.
Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected HLA-A in Human tonsil tissue sections.
Flow Cytometry Analysis: 0.1 µg from a representative lot detected HLA-A in one million Raji cells.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
HLA class I histocompatibility antigen, A alpha chain (UniProt: P04439; also known as Human leukocyte antigen A, HLA-A) is encoded by the HLA-A (also known as HLAA) gene (Gene ID: 3105) in human. HLA-A is a single-pass type I membrane glycoprotein that is synthesized with a signal peptide (aa 1-24), which is subsequently cleaved off to produce the mature protein that contains an extracellular domain (aa 25-308), a transmembrane domain (aa 309-332), and a cytoplasmic domain (aa 333-365). It is ubiquitous in its distribution and its levels are up-regulated by interferon- , IL-1β, and TNF. It is an antigen-presenting major histocompatibility complex I molecule that in complex with β2-microglobulin displays primary viral and tumor-derived peptides on antigen-presenting cells for recognition by -β T cell receptor (TCR) on HLA-A-restricted CD8+ T cells. This helps antigen-specific T cell immune response to eliminate infected or transformed cells. It may also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. It typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via interferon- -induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme. Only optimally assembled peptide-HLA- β2-microglobulin trimer is reported to translocate to the surface of antigen-presenting cells, where it interacts with TCR and CD8 co-receptor on the surface of T cells. Two isoforms of HLA-A have been described that are produced by alternative splicing. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.(Ref.: Parmentier, N., et al. (2010). Nat. Immunol. 11(5); 449-454; Robek, MD., et al. (2007). J. Virol. 81(2); 483-491).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.